Abstract
Abstract: :
Purpose: To compare the efficacy and safety of prednisolone acetate 1% and 1% rimexolone ophthalmic suspension in the treatment of acute anterior uveitis (AAU) in HLA-B27 + patients. Methods: Sixty - nine AAU HLA-B27+ patients were randomly selected for treatment with prednisolone acetate 1% (Group A) or rimexolone 1% (Group B). All patients showed mild to moderate anterior chamber inflammation. Intraocular pressure and inflammation were recorded weekly during six weeks. It was a prospective, randomized, double blind, clinical trial. Results: There was no a statistically significant difference among group A and B when anterior chamber flare and cells were measured. In both groups the IOP raised above the basal value at the first week (12.5% for prednisolone and 10.25% for rimexolona), however at the end of the study the IOP was lower in the group B (6.1% above the basal value) than in the Group A ( 19.66% above the basal value) this difference was not statistically significant (p = 0.55). Conclusion: Rimexolone 1% is as effective as Prednisolone acetate 1% in the treatment of mild to moderate AAU HLA-B27 +. Final IOP in both groups was similar.
Keywords: 612 uveitis-clinical/animal model • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 437 inflammation